• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ONTX

    Onconova Therapeutics Inc.

    Subscribe to $ONTX
    $ONTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: onconova.com

    Peers

    $ALRN
    $ATHE
    $CLDX
    $CDTX
    $CBAY
    $MCRB

    Recent Analyst Ratings for Onconova Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    3/1/2022$7.00Buy
    Ladenburg Thalmann
    See more ratings

    Onconova Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Onconova Therapeutics with a new price target

      Ladenburg Thalmann initiated coverage of Onconova Therapeutics with a rating of Buy and set a new price target of $7.00

      3/1/22 7:21:18 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Onconova Therapeutics with a new price target

      Guggenheim initiated coverage of Onconova Therapeutics with a rating of Buy and set a new price target of $4.00

      5/18/21 6:31:16 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Onconova Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Onconova Expands Leadership Team with Two Key Appointments

      Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D). "We are delighted to have Dr. Moyo and Ms. Arora as integral members of our team at Onconova as we prepar

      10/24/23 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

      NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company's Board of Directors. "It is my pleasure to welcome Peter and Trafford to our Board," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "Their track record of successfully building and leading teams tasked with the discovery, development, and delivery of novel therapies is impressive. I look forward to benefiti

      12/19/22 4:05:23 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

      NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. "Adar's deep scientific expertise in oncology and business development experience at leading biotechnology companies, most recently at Amgen, make her an excellent addition to our team at Onconova," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "We are thrilled to have her join us and look forward to benefitting from her insights. Her str

      12/13/21 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer

      NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) --  Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as Chief Medical Officer (CMO), effective as of June 14, 2021. "Mark's extensive experience leading clinical oncology programs at all stages of development makes him an ideal fit for Onconova. He will add great depth to our management team," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "His wide ranging medical and scientific expertise, which notably covers the deve

      6/1/21 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Onconova Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)

      3/A - Traws Pharma, Inc. (0001130598) (Issuer)

      4/12/24 4:11:22 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)

      3/A - Traws Pharma, Inc. (0001130598) (Issuer)

      4/11/24 5:41:38 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redfield Robert was granted 97,500 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 8:07:09 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pauza Charles David was granted 97,500 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 8:04:16 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cautreels Werner was granted 200,000 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 8:03:08 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savchuk Nikolay was granted 2,664,869 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 8:01:52 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dukes Iain D. was granted 1,779,337 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 7:59:53 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Viriom, Inc. claimed ownership of 1,645,100 shares (SEC Form 3)

      3 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 7:57:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Orbimed Advisors Llc claimed ownership of 885,532 shares (SEC Form 3)

      3 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 7:56:28 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Redfield Robert

      3 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 7:55:26 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Onconova Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

      Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results a

      11/14/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

      NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing: (800) 715-9871 for domestic or(646

      11/7/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

      Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma based on a constructive Type B FDA meeting held in June Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported second quarter 2023 financial results a

      8/10/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023

      NEWTOWN, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its second quarter 2023 financial results on Thursday, August 10, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing: (800) 715-9871 for domestic and(64

      8/3/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

      NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) --  Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March 31, 2023, and provided a business update. Highlights for the first quarter of 2023 and recent weeks include: The first participant was dosed in the Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). The trial remains on track for a preliminary data readout from its Phase 1 portion in the fourth quarter of this year.Safe

      5/15/23 4:18:05 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

      NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2023 financial results on Monday, May 15, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing (800) 715-9871 for domestic and (646) 307-1

      5/4/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

      NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business update. Highlights for the fourth quarter of 2022 and recent weeks include: Based upon encouraging safety findings from its ongoing Phase 1 program, Onconova intends to administer narazaciclib orally with a continuous daily dosing schedule in upcoming clinical trials. Results from the Phase 1 solid tumor trial evaluating a continuous daily dosing regimen of

      3/16/23 4:04:44 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

      NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing (800) 715-9871 for domestic and (646) 3

      3/9/23 4:05:04 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

      Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). In addition, the Company reported its third quarter 2022 financial results and provided a business update. "Onconova's upcoming Phase 1/2a trial has

      11/14/22 4:05:08 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022

      NEWTOWN, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2022 financial results on Monday, November 14, 2022. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing (800) 715-9871 for domestic and (646) 307-1963 for int

      11/7/22 4:05:15 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Onconova Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Onconova Therapeutics Inc.

      SC 13D - Traws Pharma, Inc. (0001130598) (Subject)

      4/8/24 9:37:11 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Onconova Therapeutics Inc. (Amendment)

      SC 13G/A - Onconova Therapeutics, Inc. (0001130598) (Subject)

      2/14/22 3:20:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Onconova Therapeutics, Inc.

      SC 13G - Onconova Therapeutics, Inc. (0001130598) (Subject)

      10/1/21 11:01:51 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Onconova Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Traws Pharma Announces New Employee Inducement Grants

      NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company"))) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the "Merger"). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter (1/4) of the shares subject to each restricted stock equity awar

      4/2/24 7:15:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

      Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir in 2024, with first top-line read-outs expected in H2 2024Traws Pharma to be led by incoming CEO, Werner Cautreels, Ph.D. Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) alo

      4/2/24 7:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

      NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. "The ability to impact multiple targets is an important characteristic of Onconova's two lead clinical programs, rigosertib and naraz

      3/8/24 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

      Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings Early Phase 1/2 studies suggest potential for an improved profile and daily dosing Dose escalation is underway in lead indication of Low Grade Endometrioid Endometrial Carcinoma (LGEEC), with plans to define the Recommended Phase 2 Dose (RP2D) and prepare for registrational studies, with a planned update in H1 2024 NEWTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focu

      12/12/23 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

      Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors Data support the potential use of narazaciclib in breast and ovarian cancers Narazaciclib progressing towards RP2D and preparation for registrational studies, with a planned update in H1 2024 NEWTOWN, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclin

      12/8/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

      NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL. Presentation Details Date/Time:Monday, December 4, 2023, 10:30 AM ET followed by a Breakout SessionSpeaker:Steven Fruchtman, M.D., President & CEO1X1 meetings:The Onconova Managem

      11/28/23 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

      Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results a

      11/14/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

      NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing: (800) 715-9871 for domestic or(646

      11/7/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

      Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023. "The poster that we

      11/2/23 10:37:27 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Expands Leadership Team with Two Key Appointments

      Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D). "We are delighted to have Dr. Moyo and Ms. Arora as integral members of our team at Onconova as we prepar

      10/24/23 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Onconova Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)

      10-K/A - Traws Pharma, Inc. (0001130598) (Filer)

      4/29/24 4:06:03 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Onconova Therapeutics Inc.

      D - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:15:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Onconova Therapeutics Inc.

      DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:09:29 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:06:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Onconova Therapeutics Inc.

      10-K - Onconova Therapeutics, Inc. (0001130598) (Filer)

      4/1/24 4:08:19 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Onconova Therapeutics, Inc. (0001130598) (Filer)

      9/29/23 5:00:13 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Onconova Therapeutics, Inc. (0001130598) (Filer)

      8/15/23 4:15:23 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Onconova Therapeutics Inc.

      10-Q - Onconova Therapeutics, Inc. (0001130598) (Filer)

      8/14/23 5:28:32 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Onconova Therapeutics, Inc. (0001130598) (Filer)

      8/10/23 5:18:49 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Onconova Therapeutics Inc.

      DEFA14A - Onconova Therapeutics, Inc. (0001130598) (Filer)

      7/21/23 4:50:14 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care